Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil blocks the AT1 receptors that normally bind angiotensin II. By preventing this binding, it stops angiotensin‑II‑induced vasoconstriction and aldosterone release, leading to relaxed blood vessels and reduced sodium‑water retention, which together lower arterial pressure.

The specific dose of Olmetec Plus is determined by the prescribing clinician based on the patient’s blood‑pressure readings, kidney function, and other individual factors. Only a qualified health professional should set the dosage and adjust it as needed.

Safety of Olmetec Plus in pregnancy has not been established, and it is generally avoided unless the potential benefit justifies the risk. Limited data are available for breastfeeding; therefore, a healthcare provider should evaluate the risk‑benefit ratio before use.

To order Olmetec Plus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Olmetec Plus offers a dual mechanism—angiotensin II blockade plus thiazide‑induced diuresis—providing more potent blood‑pressure reduction than many single‑agent therapies. Compared with ACE inhibitors, it has a lower incidence of cough, and compared with beta‑blockers, it does not affect heart rate. Choice of therapy depends on patient comorbidities and tolerance.

Store Olmetec Plus at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat. Do not use if the packaging is damaged or if the tablets appear discolored.

Olmetec Plus is taken orally, usually once daily, with a full glass of water. It may be taken with or without food, but consistent timing each day helps maintain stable blood‑pressure control. Swallow the tablet whole; do not crush or chew unless instructed by a healthcare professional.

Serious risks include severe hypotension, acute kidney injury, marked electrolyte disturbances such as hyperkalemia, and rare allergic reactions like angioedema. Patients should be monitored for sudden drops in blood pressure, changes in kidney function, and any signs of rash or swelling, and seek medical attention promptly if they occur.

Olmetec Plus is contraindicated in patients with known hypersensitivity to olmesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, anuria, or those who are pregnant unless the benefit outweighs the risk. Clinicians must assess each patient’s medical history before prescribing.